featured
2023 Top Story in Diabetes: The SELECT Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563. Online ahead of print.
-
Inzucchi SE. Semaglutide and Cardiovascular Outcomes in Patients With Obesity Without Diabetes [abstract of Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563. Online ahead of print]. PracticeUpdate Diabetes 2023 Nov 23. Accessed November 22, 2023.
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-622.
Disclosure statements are available on the authors' profiles: